Free shipping on all orders over $ 500

Acalabrutinib

Cat. No. M5306

All AbMole products are for research use only, cannot be used for human consumption.

Acalabrutinib Structure
Synonym:

ACP-196

Size Price Availability Quantity
5mg USD 45  USD45 In stock
10mg USD 75  USD75 In stock
25mg USD 120  USD120 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

In vitro: In the in vitro signaling assay on primary human CLL cells, acalabrutinib inhibits tyrosine phosphorylation of downstream targets of ERK, IKB, and AKT. Acalabrutinib demonstrates higher selectivity for BTK with IC50 determinations on nine kinases with a cysteine residue in the same position as BTK. Importantly, unlike ibrutinib, acalabrutinib does not inhibit EGFR, ITK, or TEC. acalabrutinib has no effect on EGFR phosphorylation on tyrosine residues Y1068 and Y1173. Compared with ibrutinib, acalabrutinib has much higher IC50(>1000 nM) or virtually no inhibition on kinase activities of ITK, EGFR, ERBB2, ERBB4, JAK3, BLK, FGR, FYN, HCK, LCK, LYN, SRC, and YES1.

In vivo: oral administration of ACP-196 in mice results in dose-dependent inhibition of anti-IgM-induced CD86 expression in CD19+ splenocytes with an ED50 of 0.34 mg/kg compared to 0.91 mg/kg for ibrutinib. A similar model is used to compare the duration of Btk inhibition after a single oral dose of 25 mg/kg. ACP-196 inhibits CD86 expression >90% at 3h postdose.

Chemical Information
Molecular Weight 465.51
Formula C26H23N7O2
CAS Number 1420477-60-6
Solubility (25°C) 80 mg/mL in DMSO
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Wu J, et al. J Hematol Oncol. Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor.

[2] Byrd JC, et al. N Engl J Med. Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.

Related BTK Products
BIIB129

BIIB129 is a covalent, selective inhibitor of Bruton's tyrosine kinase (BTK) capable of penetrating the blood-brain barrier. BIIB129 inhibits the activity of BTK by covalently binding to Cys481 in BTK, thereby affecting the function of B cells and myeloid cells.

UBX-382 

UBX-382 is an orally available proteolysis-targeting chimeras (PROTACs) that target BTK to inactivate B-cell receptor signaling.

GDC-0834 

GDC-0834 is a potent and selective BTK inhibitor.

DD-03-171 

DD-03-171 is a BTK, IKFZ1 and IKFZ3 degrader, the BTK IC50 a value of 5.1 nM.

N-piperidine Ibrutinib hydrochloride 

N-piperidine Ibrutinib hydrochloride is a reversible Ibrutinib derivative.

  Catalog
Abmole Inhibitor Catalog




Keywords: Acalabrutinib, ACP-196 supplier, BTK, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.